Global burden, geographic and sex disparities, and projections to 2050 for salivary gland cancer across G20 countries: a GLOBOCAN 2024 analysis
- 1Department of Oral and Maxillofacial Surgery, Suining First People’s Hospital
Abstract
Background: Salivary gland cancer is uncommon, and neither its distribution nor its trajectory across the G20 has been well described. Using the GLOBOCAN 2024 case counts, we described the 2024 burden in the 19 G20 member economies and in four HDI aggregates, and examined HDI-related gradients in population-level proxies for survival.
Methods: We analyzed the GLOBOCAN 2024 case counts for salivary-gland cancer (ICD-10 C07–C08) in the 19 G20 member economies and four HDI groups. Age-standardized incidence (ASIR) and mortality (ASMR) rates, 5-year prevalence, and the mortality-to-incidence (MIR) and prevalence-to-mortality (PMR) ratios were tabulated by country, HDI group and sex, and related to HDI using Spearman rank correlation. Projections to 2050 follow the GLOBOCAN 2024 Cancer Tomorrow default demographic scenario, applying the 2024 case counts and age-specific rates to United Nations population projections.
Results: In 2024 the G20 recorded 37,812 cases and 12,661 deaths, 46.2% of them in China and India. At country level, the HDI–MIR correlation was not significant (r = −0.04, 95% CI −0.48 to 0.42; P = 0.88), although MIR was highest in the low-HDI group (0.53) and lowest in the very-high-HDI group (0.34) and PMR varied 3.9-fold across aggregates. Male MIR exceeded female MIR in 16 of the 17 economies for which the ratio was computable, the sole exception being Türkiye. Holding 2024 age-specific rates constant, deaths at ages ≥75 years would rise by 152.8% by 2050; growth would be largest in the low- and medium-HDI aggregates (+134.4% and +96.1%) and smallest in Japan (+8.4%).
Conclusion: The G20 burden was highly heterogeneous. Across the global HDI aggregates the burden followed development level, with the highest MIR in the low-HDI group, but this ordering did not carry over to a country-level HDI–MIR correlation among the 19 member economies. Projected growth was concentrated in low- and medium-HDI settings, which argues for strengthening diagnostic capacity and survivorship measurement there.
Related
- Burden, trends, and projections of prostate cancer: global cancer statistics (GLOBOCAN) estimates for 2024 and 2022
- Global and registry-based patterns of pancreatic cancer: GLOBOCAN 2020, CI5plus trends (2000–2017), and demographic projections to 2040
- Burden and Projections of Premenopausal and Postmenopausal Breast Cancer Worldwide: A Comprehensive Analysis of GLOBOCAN 2022 Data
- Racial, sex, and geographic disparities in mortality involving stroke and chronic kidney disease: a CDC WONDER database analysis, 1999–2020
- Close but unreachable: racial disparities in hospice utilization beyond geographic proximity among older adult patients with cancer
BibTeX
@article{yang2026global,
title = {{Global burden, geographic and sex disparities, and projections to 2050 for salivary gland cancer across G20 countries: a GLOBOCAN 2024 analysis}},
author = {Wen Yang and Yuzhen Ma and Chunxia Shu},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1995714},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1995714/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Global burden, geographic and sex disparities, and projections to 2050 for salivary gland cancer across G20 countries: a GLOBOCAN 2024 analysis
AU - Wen Yang
AU - Yuzhen Ma
AU - Chunxia Shu
PY - 2026
DA - 2026/10/26
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1995714
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1995714/full
AB - Background: Salivary gland cancer is uncommon, and neither its distribution nor its trajectory across the G20 has been well described. Using the GLOBOCAN 2024 case counts, we described the 2024 burden in the 19 G20 member economies and in four HDI aggregates, and examined HDI-related gradients in population-level proxies for survival. Methods: We analyzed the GLOBOCAN 2024 case counts for salivary-gland cancer (ICD-10 C07–C08) in the 19 G20 member economies and four HDI groups. Age-standardized incidence (ASIR) and mortality (ASMR) rates, 5-year prevalence, and the mortality-to-incidence (MIR) and prevalence-to-mortality (PMR) ratios were tabulated by country, HDI group and sex, and related to HDI using Spearman rank correlation. Projections to 2050 follow the GLOBOCAN 2024 Cancer Tomorrow default demographic scenario, applying the 2024 case counts and age-specific rates to United Nations population projections. Results: In 2024 the G20 recorded 37,812 cases and 12,661 deaths, 46.2% of them in China and India. At country level, the HDI–MIR correlation was not significant (r = −0.04, 95% CI −0.48 to 0.42; P = 0.88), although MIR was highest in the low-HDI group (0.53) and lowest in the very-high-HDI group (0.34) and PMR varied 3.9-fold across aggregates. Male MIR exceeded female MIR in 16 of the 17 economies for which the ratio was computable, the sole exception being Türkiye. Holding 2024 age-specific rates constant, deaths at ages ≥75 years would rise by 152.8% by 2050; growth would be largest in the low- and medium-HDI aggregates (+134.4% and +96.1%) and smallest in Japan (+8.4%). Conclusion: The G20 burden was highly heterogeneous. Across the global HDI aggregates the burden followed development level, with the highest MIR in the low-HDI group, but this ordering did not carry over to a country-level HDI–MIR correlation among the 19 member economies. Projected growth was concentrated in low- and medium-HDI settings, which argues for strengthening diagnostic capacity and survivorship measurement there.
SN - 2234-943X
ER -